WO2017136350A1 - Anticorps anti-c3b aglycosylés et leurs utilisations - Google Patents

Anticorps anti-c3b aglycosylés et leurs utilisations Download PDF

Info

Publication number
WO2017136350A1
WO2017136350A1 PCT/US2017/015856 US2017015856W WO2017136350A1 WO 2017136350 A1 WO2017136350 A1 WO 2017136350A1 US 2017015856 W US2017015856 W US 2017015856W WO 2017136350 A1 WO2017136350 A1 WO 2017136350A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
aac3b
antigen binding
binding fragment
antibodies
Prior art date
Application number
PCT/US2017/015856
Other languages
English (en)
Inventor
Rekha Bansal
Original Assignee
Novelmed Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/012,457 external-priority patent/US20190202898A9/en
Application filed by Novelmed Therapeutics, Inc. filed Critical Novelmed Therapeutics, Inc.
Publication of WO2017136350A1 publication Critical patent/WO2017136350A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the complement system is activated via three distinct pathways; the classical pathway (CP), the lectin pathway, and the alternative complement pathway (AP).
  • the classical pathway (CP) is activated via antigen- antibody complexes.
  • the lectin pathway is a variation of the classical pathway and the alternative pathway (AP) is activated by foreign material, artificial surfaces, dead tissues, bacteria, and dead yeast cells.
  • the classical complement pathway is important for host defense against pathogens. Activation of the classical pathway generates C3a, C4a, C5a and C5b-9 molecules, which activates a variety of cells in response to host defense.
  • anaphylatoxins C3a, C5a are formed and tissues damaging C5b-9 molecules, also known as the membrane attack complex (MAC), are formed.
  • MAC membrane attack complex
  • the alternative complement pathway is activated in pathological inflammation. Elevated levels of C3a, C5a, and C5b-9 have been found associated with multiple acute and chronic disease conditions. These inflammatory molecules activate neutrophils, monocytes and platelets. Therefore, inhibition of disease-induced AP activation is important for clinical benefit in the diseases where complement activation plays a role in disease pathology.
  • the complement system contributes to tissue damage in many clinical conditions.
  • the activities included in the complement biochemical cascade present a potential threat to host tissue.
  • An example includes the indiscriminate release of destructive enzymes possibly causing host cell lysis.
  • C3a and C5a are mediated by the activation of the complement pathways.
  • Both of the anaphylatoxins C3a and C5a are known to activate leukocytes and platelets.
  • a frequent indicator of cellular activation is the cellular expression of CD1 lb on leukocytes, and CD62P on platelets.
  • the release of several inflammatory molecules is triggered by the platelet- leukocyte binding mediated by these activation markers.
  • One result of such conjugate formation is the removal of platelets from the circulation, a phenomenon that can contribute to the development of thrombocytopenia.
  • Embodiments described herein relate to an aglycosylated or aglycosyl anti-C3b (AAC3b) antibody or antigen (i.e., C3b) binding fragment thereof that binds C3b and inhibits alternative pathway activation and C3 dependent complement activation, and particularly relates to an aglycosylated or aglycosyl humanized anti-C3b antibody that binds C3b and inhibits C3 dependent complement activation.
  • the AAC3b antibody or antigen binding fragment thereof can be used to treat a complement-mediated disease in a subject in need thereof.
  • the AAC3b antibody or antigen binding fragment thereof includes a modification at the conserved N-linked site of the CH2 domain of the Fc portion of the antibody.
  • the modification can include a mutation in the heavy chain glycosylation site that prevents glycosylation at the site.
  • the modification includes a mutation of N298Q (N297 using EU Kabat numbering).
  • the modification includes a mutation of N298A (N297 using EU Kabat numbering).
  • the modification includes the removal of the CH2 domain glycans. The modification can prevent glycosylation at the CH2 domain.
  • the AAC3b antibody or antigen binding fragment thereof can include a humanized heavy chain aglycosylated region having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 24-57.
  • the AAC3b antibody or antigen binding fragment thereof does not bind to an Fc effector receptor and/or cause cellular lysis.
  • the AAC3b antibody or antigen binding fragment thereof is selected from the group consisting of: monoclonal antibodies, polyclonal antibodies, murine antibodies, chimeric antibodies, primatized antibodies, and humanized antibodies.
  • the AAC3b antibody or antigen binding fragment thereof is selected from the group consisting of: multimeric antibodies, heterodimeric antibodies, hemidimeric antibodies, tetravalent antibodies, bispecific antibodies, Fab, Fab', Fab'2, F (v) antibody fragments, and single chain antibodies or derivatives thereof.
  • the AAC3b antibody or antigen binding fragment thereof can be an aglycosylated humanized antibody of the murine monoclonal antibody produced by a hybridoma cell deposited under ATCC Accession No. PTA-8806.
  • the AAC3b antibody or antigen binding fragment thereof can have a heavy chain variable domain including 3CDRs having the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 and a light chain variable domain including 3CDRs having amino acid sequences of SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21.
  • the heavy chain variable domain can have an amino acid sequence at least 90% identical to SEQ ID NO: 1.
  • the heavy chain variable domain can have an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12, SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; and SEQ ID NO: 17.
  • the light chain variable domain can have an amino acid sequence selected from the group consisting of SEQ ID NO: 18; SEQ ID NO: 22; and SEQ ID NO: 58.
  • the AAC3b antibody, antigen binding fragment thereof, or pharmaceutical composition thereof can be administered to a subject by injection, intravenously, subcutaneously, intravitreally, intraperitoneally, intramuscularly,
  • AAC3b antibody, antigen binding fragment thereof, or pharmaceutical composition thereof relate to a method of inhibiting alternative complement pathway in a subject in need thereof by administering to the subject an inhibiting amount of an AAC3b antibody, antigen binding fragment thereof, or pharmaceutical composition thereof.
  • the AAC3b antibody or antigen binding fragment thereof includes a mutation of one the asparagine residue (N297 using EU Kabat numbering) at the conserved N-linked sites in the CH2 domains of the Fc portion of the antibody. The mutation prevents glycosylation at the site and does not contribute to the binding and functional properties of the antibody.
  • the AAC3b antibody or antigen binding fragment thereof can display similar characteristics for function and affinity binding to C3b as a murine anti- C3b antibody (AC3b antibody), such as an AC3b antibody produced by the hybridoma cell line deposited under ATCC Accession No. PTA-8806.
  • AC3b antibody murine anti- C3b antibody
  • the AAC3b antibody or antigen binding fragment thereof can inhibit binding of C3b to Factor B at the same concentration as the AC3b antibody.
  • the AAC3b antibody can also specifically bind to the same epitope as the AC3b antibody or compete with AC3b antibody for C3b binding.
  • the AAC3b antibody or antigen binding fragment thereof can include at least one of the following properties: specifically bind C3b and prevent formation of C3a and C3b; specifically bind C3b and prevent formation of C5a and C5b, specifically bind C3b and prevent formation of SC5b-9, C5b-6, C5b-7, C5b-8, and C5b-9, specifically bind C3b and prevent formation and deposition of C3b, specifically bind C3b and prevent formation and deposition of PC3b, specifically bind C3b and prevent formation and deposition of PC3bBb, specifically bind C3b and prevent formation and deposition of (P)n(C3b)n(Bb)n where n is equal to any value between 1 to 10, specifically bind C3b and prevent activation of neutrophils, monocytes, and platelets via the inhibition of AP, specifically bind C3b and prevent formation of various cytokines including VEGF and IL-1, specifically bind C3b
  • the AAC3b antibody or antigen binding fragment thereof can be conjugated to a detectable marker, therapeutic agent, imaging agent, or radionuclide.
  • the detectable marker can be, for example, a radioactive isotope, enzyme, dye, or biotin.
  • the therapeutic agent can be, for example, a radioisotope, radionuclide, toxin, toxoid or chemotherapeutic agent.
  • the imaging agent can be a labeling moiety, biotin, a fluorescent moiety, a radioactive moiety, a histidine tag, or a peptide tag.
  • Still other embodiments relate to a pharmaceutical composition that includes an AAC3b antibody and a pharmaceutically acceptable carrier.
  • the AAC3b antibody or antigen binding fragment thereof binds C3b and inhibits alternative pathway activation and particularly C3 dependent complement activation.
  • the AAC3b antibody or antigen binding fragment thereof can be used to treat a complement-mediated disease in a subject in need thereof.
  • the AAC3b antibody or antigen binding fragment thereof can include a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody.
  • the modification can include a mutation in the heavy chain glycosylation site that prevents glycosylation at the site.
  • the modification includes a mutation of N298Q (N297 using EU Kabat numbering).
  • the modification includes a mutation of N298A (N297 using EU Kabat numbering).
  • the modification includes the removal of the CH2 domain glycans. The modification can prevent glycosylation at the CH2 domain.
  • the pharmaceutical composition can further include an immunosuppressive or immunomodulatory compound.
  • the pharmaceutical composition can also include a buffer at a pH 6 to 6.5.
  • the AAC3b antibody or antigen binding fragment thereof can be provided in the formulation in the range of about 20 mg/mL to about
  • 200 mg/mL for example, about 50 mg/ml to about 100 mg/ml.
  • AAC3b antibody or antigen binding fragment thereof can include a modification at the conserved N-linked site in the CH2 domains of the Fc portion of the antibody.
  • the modification can include a mutation in the heavy chain glycosylation site that prevents glycosylation at the site.
  • the modification includes a mutation of N298Q (N297 using EU Kabat numbering).
  • the modification includes a mutation of N298A (N297 using EU Kabat numbering).
  • the modification includes the removal of the CH2 domain glycans. The modification can prevent glycosylation at the CH2 domain.
  • the AAC3b antibody, antigen binding fragment thereof, or pharmaceutical composition thereof can be administered to the subject in any manner that is medically acceptable, such as by oral, nasal, ophthalmic, rectal, and topical routes.
  • the AAC3b antibody, antigen binding fragment thereof, or pharmaceutical composition thereof can be administered, orally in the form of capsules, tablets, aqueous suspensions or solutions, topically by application of a cream, ointment or the like, by inhalation through the use of a nebulizer, a dry powder inhaler or a metered dose inhaler, or by sustained release
  • the AAC3b antibody, antigen binding fragment thereof, or pharmaceutical composition thereof can be administered to the subject in multiple doses per day, repeatedly at intervals ranging from each day to every other month, or at intervals for as long a time as medically indicated, ranging from days or weeks to the life of the subject.
  • Still other embodiments relate to a method for inhibiting alternative complement pathway but not activating the classical pathway in a subject by administering to the subject a therapeutically effective amount of an AAC3b antibody or antigen binding fragment thereof.
  • the AAC3b antibody or antigen binding fragment thereof can include a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody.
  • the modification can include a mutation in the heavy chain glycosylation site that prevents glycosylation at the site and CI Q binding so that the AAC3b antibody or antigen binding fragment thereof does not activate the classical complement pathway.
  • the AAC3b antibody or antigen binding fragment thereof does not bind C1Q and prevents C1Q mediated activation of the classical pathway, does not block classical pathway activation, and/or does not participate in the classical pathway activation.
  • AAC3b antibody or antigen binding fragment thereof can include a
  • the modification can include a mutation in the heavy chain glycosylation site that prevents glycosylation at the site.
  • the modification includes a mutation of N298Q (N297 using EU Kabat numbering).
  • the modification includes a mutation of N298A (N297 using EU Kabat numbering). The mutation can prevent binding to the Fc receptors on a variety of cells and the AAC3b antibody or antigen binding fragment thereof does not activate the cells via Fc activation.
  • the AAC3b antibody or antigen binding fragment thereof does not bind to Fc receptors selected from the group comprising; CD16a, CD16b, CD32a, CD32b, CD32c, and CD64 and therefore prevents Fc activation on cells.
  • the Fc receptors,CD16a, CD16b, CD32a, CD32b, CD32c, and CD64 can be present on cells selected from the group comprising Neutrophils, monocytes, platelets, T lymphocytes, NK cells, basophils, and eosinophils, and activation of such cells is prevented by administering the the AAC3b antibody or antigen binding fragment thereof to the cells.
  • the cells can also cause inflammatory and thrombotic events, which are prevented with administration of the AAC3b antibody or antigen binding fragment thereof to the cells.
  • Still other embodiments relate to a method for inhibiting, treating, preventing complement-mediated disease in a subject by administering to the subject a therapeutically effective amount of the AAC3b antibody or antigen binding fragment thereof to the subject.
  • the complement-mediated disease can be selected from the group consisting of:
  • FIG. 1 Another embodiments relate to a method of imaging cells, organs, tissues in a subject that express the antigen C3b (the immunogen of the Anti-C3b antibody) or its fragments that is specifically recognized by the AAC3b antibody or AC3b antibody comprising the steps of: (a) administering to the subject an effective amount of an imaging composition comprising the AAC3b antibody, AC3b antibody, or antigen binding fragment thereof under conditions permitting the formation of a complex between the AAC3b antibody, AC3b, or antigen binding fragment thereof and the protein on the surface of cells, tissues, or organs; and (b) imaging any antibody/protein complex or antibody
  • Still other embodiments relate to a method for detecting the presence of C3b positive cells in a subject that express C3b that is specifically recognized by the AAC3b antibody or AC3b antibody comprising the steps of: (a) administering to the subject an effective amount of an imaging agent comprising the AAC3b antibody, AC3b antibody, or antigen binding fragment thereof under conditions permitting the formation of a complex between the antibody or antibody derivative and the protein; (b) clearing any unbound imaging agent from the subject ; and (c) detecting the presence of any antibody/protein complex or antibody derivative/complex formed, the presence of such complex indicating the presence of disease cells in the subject
  • FIG. 1 illustrates a plot showing that the AAC3b antibody binds substrate-bound C3b with high affinity of 100 pM using an ELISA assay.
  • ELISA wells were coated with Factor C3b at a fixed concentration.
  • AAC3b at various concentrations in solution were allowed to bind and the data was fitted using Origin graphing program.
  • FIG. 2 illustrates a plot showing that the AAC3b antibody inhibits alternative pathway dependent hemolysis of erythrocytes in 90% NHS.
  • AAC3b inhibits hemolysis in a dose-dependent manner with approximately 50 nM antibody required to neutralize the C3b in undiluted normal human serum.
  • various concentrations of AAC3b antibody were added to undiluted human serum and the mixture was subjected to AP hemolysis. The data demonstrates that AP Hemolysis is inhibited in human serum.
  • FIG. 3 illustrates a plot showing AAC3b antibody inhibits AP hemolysis without inhibiting CP hemolysis. This study was conducted in whole blood. Whole human blood from six individuals was treated with the AAC3b antibody. As shown the AAC3b antibody did not inhibit CP but AP is inhibited as usual.
  • FIG. 4 illustrates a plot showing that AAC3b antibody does not bind C1Q.
  • Avastin was used as a positive control and, as expected, binds C1Q present in serum.
  • AAC3b antibody has no binding suggesting that the AAC3b antibody has reduced C1Q binding and therefore lack of CP activation and less effector function.
  • FIG. 5 illustrates a plot showing the results of C3 convertase formation.
  • AAC3b antibody inhibits C3 convertase formation in a dose-dependent formation. Inhibition of properdin binding in a dose-dependent manner reflects the inhibition of C3 convertase formation (PC3bBb).
  • ELISA plates were coated with LPS and incubated in Normal human serum at 10% in AP buffer.
  • FIG. 6 illustrates a plot showing the results of C3 convertase formation.
  • AAC3b antibody inhibits C3 convertase formation in a dose-dependent formation.
  • Inhibition of C3b deposition on the LPS in a dose-dependent manner reflects the inhibition of C3 convertase formation (PC3bBb).
  • ELISA plates were coated with LPS and incubated in Normal human serum at 10% in AP buffer.
  • FIG. 7 illustrates a plot showing the results of C3 convertase formation.
  • AAC3b antibody inhibits C3 convertase (PC3bBb) formation in a dose-dependent formation.
  • Inhibition of Bb formation is inhibited in a dose-dependent manner reflects the inhibition of C3 convertase formation (PC3bBb).
  • ELISA plates were coated with LPS and incubated in Normal human serum at 10% in AP buffer. The Bb was detected with an anti-Factor B antibody.
  • FIG. 8 illustrates a plot showing the results from a convertase formation assay.
  • detection of C5b indicates the presence of MAC (C5b-9).
  • the data shows that increasing concentrations of AAC3b antibody inhibits C5b formation.
  • FIG. 9 illustrates a plot showing the results from a convertase formation assay.
  • C5b-9 was detected with neo anti-MAC antibody which identifies deposited MAC (C5b-9).
  • the data shows that increasing concentrations of AAC3b antibody inhibits MAC formation.
  • FIG. 10 illustrates a plot showing unlabeled AC3b antibody competes with the labeled AC3b antibody for C3b binding.
  • ELISA plates were coated with C3b. Varying concentrations of unlabeled AC3b antibody were added to the fixed concentration of labeled AC3b antibody. Following a typical competition assay method. We determined that unlabeled antibody competes with the labeled antibody in a dose dependent manner.
  • FIG. 11 illustrates plots showing aglycosylated Fc does not bind to CD 16a, CD 16b or CD32a.
  • FIG. 12 illustrates plots showing aglycosylated Fc does not bind to CD32b and CD32c. It also shows substantially reduced binding to FcRn and CD64 compared to control glycosylated IgG. BIACORE methods were applied.
  • FIG. 13 illustrates various alternative constructs of the HC variable region of AAC3b antibody can be made using the consensus sequence (SEQ ID NO: 5) and making the point substitutions shown.
  • FIG. 14 illustrates schematically activation of the alternative pathway (AP) produces two potent anaphylatoxins; C3a and C5a. These anaphylatoxins activate a variety of cells. Activated cells release various inflammatory mediators that have been shown to be involved in disease pathology. Use of AAC3b is expected to prevent the formation of C3a/C3b, C5a/C5b, and MAC and therefore provide therapeutic benefit in diseases mediated or associated with complement activation.
  • AP alternative pathway
  • FIG. 15 lists the amino acid sequences of the AAC3b antibody heavy chain and light chain CDRs (SEQ ID NOs: 2-4 and SEQ ID NOs: 19-21).
  • FIG. 16 lists the amino acid sequences of humanized heavy chain variable regiond for AAC3b antibodies (SEQ ID NOs: 1, and 6-17).
  • FIGs. 17, 18, 19, and 20 list amino acid sequences of heavy chain constant regions with aglycosylation (SEQ ID NOs: 23-57).
  • FIG. 21 lists amino acid sequences of the light chain variable and constant regions (SEQ ID NOs: 18, 22, and 58).
  • alternative pathway refers to complement activation, which has traditionally been thought to arise from spontaneous proteolytic generation of C3b from complement factor C3 triggered, for example, by zymosan from fungal and yeast cell walls, lipopoly saccharide (LPS) from Gram-negative outer membranes, and rabbit erythrocytes, as well as from many pure polysaccharides, rabbit erythrocytes, viruses, bacteria, animal tumor cells, parasites and damaged cells.
  • LPS lipopoly saccharide
  • antibody encompasses antibodies and antibody fragments, which specifically bind to C3b or its polypeptides or portions, in which the antibody is derived from any antibody-producing mammal (e.g., a mouse, a rat, a rabbit, or a primate, including a human).
  • Exemplary antibodies include polyclonal, monoclonal and recombinant antibodies; multi-specific antibodies (e.g., bi-specific antibodies), humanized antibodies; murine antibodies, chimeric (i.e., mouse-human, mouse-primate, primate-human), monoclonal antibodies, and anti-idiotype antibodies, as well as de-immunized antibodies, and may be any intact molecule or fragment thereof.
  • antibody fragment refers to a portion derived from or related to a full-length anti-C3b antibody, generally including the antigen binding or variable region thereof.
  • Illustrative examples of antibody fragments include Fab, Fab', F(ab)2, F(ab')2 and Fv fragments, scFv fragments, diabodies, linear antibodies, single-chain antibody molecules and multispecific antibodies formed from antibody fragments.
  • antigen binding fragment refers to a fragment or fragments of a C3b antibody that contain the antibody variable regions responsible for antigen binding.
  • Fab, Fab' , and F(ab)2 lack the FC regions.
  • Antigen-binding fragments can be prepared from full- length antibody by protease digestion. Antigen-binding fragments may be produced using standard recombinant DNA methodology by those skilled in the art.
  • CDR complementarity-determining region
  • frame regions refers to those variable domain residues other than the CDR residues herein defined.
  • the term “competitively inhibits” refers to competitive inhibition of binding of a isolated antibody or antigen binding fragment thereof to C3b by any other molecule.
  • C3b inhibitory agent refers to any agent that binds to or interacts with C3b and effectively inhibits C3b-dependent complement activation, including anti-C3b antibodies and C3b antigen binding fragments thereof, natural and synthetic peptides.
  • C3b inhibitory agents useful in the methods described herein may reduce C3b-dependent complement activation, therefore all activation, by greater than 20%. In one embodiment, the C3b inhibitory agent reduces complement activation by greater than 90%.
  • a "chimeric antibody” is a recombinant protein that contains the variable domains and complementarity-determining regions derived from a non-human species (e.g., rodent) antibody, while the remainder of the antibody molecule is derived from a human antibody.
  • a “humanized antibody” is a chimeric antibody that comprises a minimal sequence conforming to specific complementarity-determining regions derived from non- human immunoglobulin that is transplanted into a human antibody framework. Humanized antibodies are typically recombinant proteins in which only the antibody complementarity- determining regions are of non-human origin.
  • lectin pathway refers to complement activation that occurs via the specific binding of serum and non-serum carbohydrate -binding proteins including mannan- binding lectin (MBL) and the ficolins.
  • MBL mannan- binding lectin
  • treatment refers to obtaining a desired pharmacologic, biologic, and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease.
  • Treatment covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease or at risk of acquiring the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.
  • MAC membrane attack complex
  • complement-mediated diseases refers to diseases where one or more of complement activation products have been found elevated and or associated with tissue, bodily fluids, and organs.
  • Fc effector refers to activation of a variety of cells to release potent inflammatory mediators. Fc Effector functions provide positive benefit in healthy subjects. Unnecessary Fc effectors can cause chaos in the body and can lead to significant inflammatory response and activation of inflammatory cells. Fc effector response occurs when Fc portion of the antibody binds Fc receptors. CD16a, CD16b, CD32a, CD32b, CD32c if bound the therapeutic/diagnostic antibody can turn on the signal for a cytokine storm by activation of neutrophils, monocytes, platelets, NK cells, T lymphocytes etc.
  • Such activation can not only generate a cytokine storm but can also cause thrombotic events by non-specific activation of platelets and erythrocytes.
  • the AAC3b antibody appears to have low to no binding to these receptors and therefore would be a therapeutic without Fc effector function.
  • C1Q binding refers Clq binding to the antibody Fc region which can initiate the activation of the classical pathway. By removing the glycosylation, AAC3b binding to C1Q was reduced.
  • aglycosylated or aglycosyl antibodies refers to antibodies that are aglycosylated.
  • Human antibodies are generally glycosylated naturally at asparagine residues.
  • the antibodies can be aglycosylatd by single point mutations.
  • Aglycosylation reduces C1Q interaction and provides the antibody with reduced Fc effector functions.
  • Aglycosylation is generally introduced at the N297 position of the CH2 region.
  • the position of asparagines within the CH2 may change a bit. Irrespective of the exact position, if the "N297" is changed to Q (Glutamine) or any other residue such as "A (Ala)", an aglycosylated antibody can be generated.
  • Other means of making AAC3b aglycosylated can be proposed, such as removal of CHI and CH2, removal of CH2, and or other point mutations that can cause
  • subject refers to all mammals, including, but not limited to, dogs, cats, horses, sheep, goats, cows, rabbits, pigs, humans, non-human primates, and rodents. In studies where animals are used as models to address a disease, the term subject has been used. The term subject has also been used in case of human when the drug is said to be administered in humans.
  • C3b and fragments refers to C3b which is made by the cleavage of C3 into C3b and C3a.
  • C3b is known to deposit on tissues and cells.
  • C3b can further degrade into iC3b, C3c, C3dg, and C3d.
  • One or more of these fragments have been found associated in disease pathology and therefore one can predict that complement activation has occurred. Since C3 is part of the alternative complement pathway, it is reasonable to believe that pathologies where one or more of these fragments are found deposited would be treatable by the AAC3b antibodies.
  • Embodiments described herein relate to aglycosylated or aglycosyl anti-C3b (AAC3b) antibodies and antigen binding fragments thereof with reduced effector functions and to the use of such antibodies and antigen binding fragments thereof to inhibit alternative pathway complement activation and to treat complement- mediated diseases.
  • AAC3b aglycosyl anti-C3b
  • the mechanism of action of glycosylated antibodies in treating complement-mediated diseases in vivo can be difficult to delineate as glycosylation can cause complement fixation and Fc effector function.
  • AAC3b antibodies In contrast, the mechanism of action of AAC3b antibodies is elucidated through the use of an AAC3b antibody in which Fc effector function has been reduced by a modification of the conserved N- linked site in the CH2 domains of the Fc dimer, leading to "aglycosyl" anti-C3b antibodies.
  • modifications include mutation of the conserved N- linked site in the CH2 domains of the Fc dimer, removal of glycans attached to the N-linked site in the CH2 domains and prevention of glycosylation.
  • the AAC3b antibodies described herein are particularly desirable for use in subjects where the undesirable thrombo-embolitic, Fc effector response and complement fixation activities are to be removed. Additionally, the diminished Fc effector function of the AAC3b antibodies may further reduce the unwanted activation of T-lymphocytes, NK cells, monocytes/macrophages, neutrophils, erythrocytes and platelets as all these cells bear Fc receptors.
  • the AAC3b antibody or antigen binding fragment thereof can include a modification at the conserved N-linked site in the CH2 domains of the Fc portion of the antibody.
  • the modification can include a mutation in the heavy chain glycosylation site that prevents glycosylation at the site.
  • the modification includes a mutation of N298Q (N297 using EU Kabat numbering).
  • the modification includes a mutation of N298A (N297 using EU Kabat numbering).
  • the modification includes the removal of the CH2 domain glycans. The modification can prevent glycosylation at the CH2 domain.
  • the AAC3b antibody or antigen binding fragment thereof does not bind to an Fc effector receptor and/or cause cellular lysis.
  • the AAC3b antibody or antigen binding fragment thereof can include a humanized heavy chain aglycosylated region having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 24-57.
  • the AAC3b antibody or antigen binding fragment thereof can be an aglycosylated humanized antibody of the murine monoclonal antibody produced by a hybridoma cell deposited under ATCC Accession No. PTA-8806.
  • the AAC3b antibody or antigen binding fragment thereof can have a heavy chain variable domain including 3CDRs having the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 and a light chain variable domain including 3CDRs having amino acid sequences of SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21.
  • the heavy chain variable domain can have an amino acid sequence at least 90% identical to SEQ ID NO: 1.
  • the heavy chain variable domain can have an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12, SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; and SEQ ID NO: 17.
  • the light chain variable domain can have an amino acid sequence selected from the group consisting of SEQ ID NO: 18; SEQ ID NO: 22; and SEQ ID NO: 58.
  • the AAC3b antibody or antigen binding fragment thereof can display similar characteristics for function and affinity binding to C3b as a murine anti- C3b antibody (AC3b antibody), such as an AC3b antibody produced by the hybridoma cell line deposited under ATCC Accession No. PTA-8806.
  • AC3b antibody murine anti- C3b antibody
  • the AAC3b antibody or antigen binding fragment thereof can inhibit binding of C3b to Factor B at the same concentration as the AC3b antibody.
  • the AAC3b antibody can also specifically bind to the same epitope as the AC3b antibody or compete with AC3b antibody for C3b binding.
  • the antibody can be, for example, a chimeric antibody, humanized antibody, human antibody, a humanized antibody or a chimeric antibody.
  • the CDRs within the variable region may be 90% similar to about 99% similar.
  • AAC3b antibodies described herein can recognize C3b with high affinity without any change in the functional activity.
  • the AAC3b and AC3b antibodies are capable of inhibiting the interaction between C3b and factor B.
  • the AAC3b and AC3b antibodies do not inhibit properdin binding to C3b. Both antibodies can demonstrate comparable activity in a variety of alternative complement assays shown in the examples.
  • Another aspect relates to antibodies that bind to the same epitope on C3b as the antibodies described herein. Such antibodies can be identified based on their ability to cross- compete with or competitively inhibit anti-C3b antibodies or antigen binding fragment thereof in standard C3b binding assays.
  • the binding of labeled anti-C3b antibody can compete with the unlabeled antibody or any other anti-C3b, which share the epitope with the antibodies described herein.
  • the other anti-C3b antibodies can be humanized, mouse, fully human and/or may have any other format.
  • the ability to block or compete with the antibodies described herein indicates that a C3b-binding antibody being examined binds to the same or similar epitope where the antibodies described herein bind.
  • Several type of competition assays have been used by those skilled in the art. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of antibodies being examined.
  • the antibody of the invention can detect C3b bound to cells, tissues, and substrate and therefore can be used in diagnostic procedures provided an appropriate label is chosen for detection.
  • the label can be biochemical, radioactive, or PET or those well known in the art.
  • the aglycosylated anti-C3b antibodies described herein are produced in a CHO cell-line by inserting the gene for the aglycosylated antibody.
  • Other cell lines known in the art may also be used. Technological advancement can provide advanced methods of stable cell line production that are suited for drug production for use in vivo.
  • the aglycosylated anti-C3b antibodies are able to associate with C3b in a manner that blocks, directly or indirectly the activation of C3b- bearing cells.
  • the AAC3b antibodies or antigen binding fragments thereof described herein can be used in a method of treating or preventing, in a subject, an alternative pathway-dependent condition or disease, by administering to the subject the AAC3b antibodies or antigen binding fragments thereof, at an amount effective to inhibit AP activation in the subject and thereby treat or prevent the alternative pathway-dependent condition or disease.
  • the AAC3b antibodies or antigen binding fragments thereof described herein can be used in a method of diagnosing, in a subject, alternative pathway-dependent condition or disease. The method can include administering to the subject an AAC3b antibody or antigen binding fragment thereof at an amount effective to bind surface bound C3b in the subject and thereby diagnosing alternative pathway-dependent condition or disease.
  • Still other embodiments relate to a method of inhibiting the adverse effects of Alternative Pathway (AP) -dependent complement activation in a living subject.
  • the method includes administering to a subject in need thereof, an amount of the AAC3b antibodies or antigen binding fragments thereof effective to inhibit AP-dependent complement activation.
  • compositions for inhibiting alternative pathway dependent activation that include a therapeutically effective amount of the AAC3b antibodies or antigen binding fragments thereof and a pharmaceutically acceptable carrier.
  • Such compositions can be beneficial in treating complement-mediated diseases where at least one of the following components of the alternative complement system have been identified in the human or animal subjects in disease condition, clinical trial, tissue/body fluid analysis or during animal studies. Such components are listed here for reference; C3a, C3a, C5a, C5b, sC5b-9, C5b-9, lack of CD55, lack of CD59, SC5b-9 and one or more cytokines.
  • the role of the alternative pathway in complement-mediated diseases is well documented.
  • the classical pathway is required for host defense and must remain silent.
  • the AP is triggered by damaged cells and tissue.
  • AP is triggered by tissue damage.
  • the AP consists of specific plasma proteins including complement Factors B, D, and P (Properdin).
  • the C3 convertase of the AP cleave C3 into C3a and C3b.
  • C5 convertase cleaves C5 into C5a and C5b.
  • the C5b molecules initiate the formation of membrane-attack complex (MAC, C5b-9). Formation of MAC causes further damage to tissues and organs via complement mediated attack on cell membranes.
  • MAC membrane-attack complex
  • complement proteins including sC5b-9 and C5b-9
  • sC5b-9 and C5b-9 have been found to be associated with several acute and chronic diseases. Histopathological studies have shown that there is an infiltration of inflammatory cells, including macrophages and lymphocytes, into the lesions that arise from disease exacerbation and progression. Complement protein deposition has also been identified. Elevated levels of complement proteins several knockout studies have further clarified the role of AP in complement-mediated diseases. Completion of the AP is indicated by the formation and deposition of C5b-9. Such molecules can activate cells, cause apoptosis and complete tissue injury leading to significant clinical symptoms. Currently there is much need to find a high affinity, target specific molecule with reduced effector function.
  • AP inhibitors are an unmet need; AP activation produces two potent inflammatory molecules C3a and C5a which appear to orchestrate the inflammatory response leading to significant clinical pathology in human and animal subjects.
  • C3a and C5a Driven Inflammation— C3a and C5a bind to their respective receptors on neutrophils, monocytes, and platelets and activate these cells to produce inflammatory mediators. These inflammatory mediators further promote the inflammatory response. More specifically, C3a activates monocytes and lymphocytes, resulting in the release TNF-alpha, IL-1 alpha, VEGF, PDGF, prostaglandins, histamine, IL-6 and IL-8, from the activated cells. These agents have been implicated in a wide variety of disease pathologies ranging from arthritis to hemolytic blood disorders. Thus, C3a plays important roles in a variety of clinical situations.
  • C5a can up-regulate cell adhesion, initiate the release VEGF and induce lysosomal enzyme and free radical release from both neutrophils and monocytes.
  • Activated complement byproducts C3a and C5a have been found to be present in drusen deposits.
  • C5b-9 and sC5b-9 - The terminal AP activation byproducts sC5b-9 and C5b-9 (MAC) have been found to be present in in disease tissues. Deposition of MAC on marks the onset of disease initiation and progression. Substantial MAC formation can directly cause cell death which results in tissue atrophy. However, even lesser, sublytic, concentrations of MAC can activate cell proliferation and migration, modulate cell functions, and induce inflammation. In PNH deposition of MAC can cause visual lysis of cells such as
  • Complement-mediated Diseases lists all diseases where complement components have been found in disease. Elevated levels of C3a, C3b, C5a, C5b, iC3b, C3dg, C3c, cytokines, growth factors, and MAC are all indicative of complement activation and therefore, AAC3b like molecules could provide therapeutic benefit to those suffering from diseases.
  • Complement-mediated diseases can include, for example, Inflammatory bowel disease, Rheumatoid arthritis, Rod- cone dystrophies, Acute lung injury , Acute respiratory distress syndrome (ARDS), ADAMTS-13 Deficiency, Aging choriocapillaris, aHUS, Allergic bronchitis bronchiectasis, Allergic bronchopulmonary aspergillosis (ABPA), allergy, Alzheimer's disease, AMD (wet and dry), Amyotrophic lateral sclerosis (ALS), And asbestos -induced inflammation, Anti-phospholipid syndrome (APLS), Arrhythmogenic Cardiomyopathy, Asthma, Atherosclerosis, Atypical hemolytic uremic syndrome (aHUS), Barraquer-Simons Syndrome, Behcet's disease, Berger's Disease/IgA nephropathy, Best disease (and pattern dystrophy), Bronchoconstriction, Bullous pemphigoid, C3
  • CAPS Catastrophic anti-phospholipid syndrome
  • CRVO Central retinal vein occlusion
  • Cerebral Ischemia Reperfusion Chagas Disease, Chorioretinal degenerations, Choroidal neovascularization (CNV) , Chronic obstructive pulmonary disease (COPD), Cold agglutinin disease (CAD), cone degenerations, cone-rod dystrophies, Cranial nerve damage from meningitis, Creutzfeldt-jakob disease, Crohn's disease, Cystic fibrosis, Degenerative disc disease (DDD), Degos Disease, Dermatomyositis, Diabetic
  • Nephropathy/Neuropathy Diabetic retinal microangiopathy
  • Diabetic retinopathy macular edema Diabetic retinopathy
  • Diseases presenting with thrombotic microangiopathy a condition in which thrombotic microangiopathy
  • glomerulonephritis MPGN II, Mucopolysaccharidoses, Multifocal motor neuropathy (MMN), Multiple sclerosis, Myasthenia gravis, myocardial infarction, neurological disorders, North Carolina macular dystrophy, organic dust diseases, Osteoarthritis, Parkinson's disease, Paroxysmal nocturnal hemoglobinuria (PNH), Pediatric Dense Deposit Disease, pemphigus vulgaris, photoreceptor degenerations, Polymyalgia rheumatica (PMR), Post- cardiopulmonary bypass inflammation, Post-streptococcal glomerulonephritis (PSGN), psoriasis, pulmonary embolisms and infarcts, pulmonary fibrosis, pulmonary vasculitis, Purtscher's retinopathy, Reactive airway disease syndrome, Renal cortical necrosis (RCN), Renal reperfusion injury, Respiratory syncytial virus (RSV), Retinal damage,
  • SLE erythematosus
  • Takayasu's arteritis thermal injury including bums or frostbite
  • Transplant Rejection Traumatic brain injury, Uveitis, Vascular leakage syndrome, Vasculitis, Vogt-Koyanagi-Harada syndrome, and Wegener's granulomatosis.
  • Extracorporeal circulation disorders Post-cardiopulmonary bypass
  • HELP heparin-induced extracorporeal LDL precipitation
  • ECMO extracorporeal membrane oxygenation
  • CPB cardiopulmonary bypass
  • Cardiovascular disorders acute coronary syndromes, Kawaski disease (arteritis), Takayasu's arteritis, Henoch-Schonlein purpura nephritis, vascular leakage syndrome, percutaneous coronary intervention (PCI), myocardial infarction, ischemia-reperfusion injury following acute myocardial infarction, atherosclerosis, vasculitis, immune complex vasculitis, vasculitis associated with rheumatoid arthritis (also called malignant rheumatoid arthritis), systemic lupus erythematosus-associated vasculitis, sepsis, arteritis, aneurysm, cardiomyopathy, dilated cardiomyopathy, cardiac surgery, peripheral vascular conditions, renovascular conditions, cardiovascular conditions, cerebrovascular conditions,
  • VGE venous gas embolus
  • Behcet's syndrome mesenteric/enteric vascular conditions, diabetic angiopathy, venous gas embolus (VGE), Wegener's granulomatosis, heparin-induced extracorporeal membrane oxygenation, and Behcet's syndrome.
  • Bone/Musculoskeletal diseases and disorders arthritis, inflammatory arthritis, non-inflammatory arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic juvenile rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus (SLE), Behcet's syndrome, and Sjogren's syndrome.
  • Transplantation diseases and disorders transplant rejection, xenograft rejection, graft versus host disease, xenotransplantation of organs or grafts, allotransplantation of organs or grafts, and hyperacute rejection.
  • ATD choroidal neovascularization
  • CNV choroidal neovascularization
  • retinal damage diabetic retinopathy, diabetic retinal microangiopathy, histoplasmosis of the eye, uveitis, diabetic macular edema, diabetic retinopathy, diabetic retinal microangiopathy, pathological myopia, central retinal vein occlusion (CRVO), corneal neovascularization, retinal neovascularization, retinal pigment epithelium (RPE), histoplasmosis of the eye, and Purtscher's retinopathy.
  • Hemoly tic/Blood diseases and disorders sepsis, systemic inflammatory response syndrome" (SIRS), hemorrhagic shock, acute respiratory distress syndrome (ARDS), catastrophic anti-phospholipid syndrome (CAPS), cold agglutinin disease (CAD), autoimmune thrombotic thrombocytopenic purpura (TTP), endotoxemia, hemolytic uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), sepsis, septic shock, sickle cell anemia, hemolytic anemia, hypereosinophilic syndrome, and anti-phospholipid syndrome (APLS).
  • SIRS systemic inflammatory response syndrome
  • ARDS acute respiratory distress syndrome
  • CAPS catastrophic anti-phospholipid syndrome
  • CAD cold agglutinin disease
  • TTP cold agglutinin disease
  • TTP cold agglutinin disease
  • HUS hemolytic uremic syndrome
  • granulomatosis transfusion-related acute lung injury
  • TRALI transfusion-related acute lung injury
  • Antiglomerular basement membrane disease Goodpasture's disease
  • eosinophilic pneumonia hypersensitivity pneumonia, allergic bronchitis bronchiec stasis, reactive airway disease syndrome, respiratory syncytial virus (RSV) infection, parainfluenza virus infection, rhinovirus infection, adenovirus infection, allergic bronchopulmonary aspergillosis (ABPA), tuberculosis, parasitic lung disease, adult respiratory distress syndrome, chronic obstructive pulmonary disease (COPD), sarcoidosis, emphysema, bronchitis, cystic fibrosis, interstitial lung disease, acute respiratory distress syndrome (ARDS), transfusion-related acute lung injury,
  • TRALI transfusion-related acute lung injury
  • RSV respiratory syncytial virus
  • ABPA allergic bronchopulmonary aspergillosis
  • COPD chronic obstructive pulmonary disease
  • Trauma-induced injuries and disorders hemorrhagic shock, hypovolemic shock, spinal cord injury, neuronal injury, cerebral trauma, cerebral ischemia reperfusion, crush injury, wound healing, severe burns, and frostbite.
  • Renal diseases and disorders renal reperfusion injury, poststreptococcal glomerulonephritis (PSGN), Goodpasture's disease, membranous nephritis, Berger's
  • Skin/Dermatologic diseases and disorders burn injuries, psoriasis, atopic dermatitis (AD), eosinophilic spongiosis, urticaria, thermal injuries, pemphigoid, epidermolysis bullosa acquisita, autoimmune bullous dermatoses, bullous pemphigoid, scleroderma, angioedema, hereditary angioneurotic edema (HAE), erythema multiforme, herpes gestationis, Sjogren's syndrome, dermatomyositis, and dermatitis herpetiformis.
  • AD atopic dermatitis
  • HAE hereditary angioneurotic edema
  • Gastrointestinal diseases and disorders Crohn's disease, Celiac Disease/gluten- sensitive enteropathy, Whipple's disease, intestinal ischemia, inflammatory bowel disease, and ulcerative colitis.
  • Endocrine diseases and disorders Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, stress anxiety, and other diseases affecting prolactin, growth or insulin-like growth factor, adrenocorticotropin release, pancreatitis, Addison's disease, diabetic conditions including, but not limited to, type 1 and type 2 diabetes, type I diabetes mellitus, sarcoidosis, diabetic retinal microangiopathy, non-obese diabetes (IDDM), angiopathy, neuropathy or retinopathy complications of IDDM or Type-2 diabetes, and insulin resistance.
  • IDDM non-obese diabetes
  • Reperfusion injuries and disorders of organs including but not limited to heart, brain, kidney, and liver.
  • Reproduction and urogenital diseases and disorders painful bladder diseases and disorders, sensory bladder diseases and disorders, spontaneous abortion, male and female diseases from infertility, diseases from pregnancy, fetomaternal tolerance, pre-eclampsia, urogenital inflammatory diseases, diseases and disorders from placental dysfunction, diseases and disorders from miscarriage, chronic bacterial cystitis, and interstitial cystitis.
  • the plate was rinsed with PBS and incubated with 1:2000 diluted peroxidase-conjugated goat anti-human monoclonal antibody. Following this incubation, the plate was rinsed and the bound peroxidase was identified using TMB reagent. TMB solution (KPL, Gaithersburg, MD) was then added and allowed to incubate for 30min at room temperature. TMB Stop solution (KPL, Gaithersburg, MD) was then added to all plate wells. Immediately following addition of stop solution, the plate(s) were read in a microplate reader at 450nm. As shown in Fig. 1, AAC3b binds C3b with 100 pM affinity.
  • Example 2 AAC3b antibody inhibits alternative pathway (AP) dependent lysis of rabbit red blood cell (rRBC) in minimally diluted normal human serum (NHS)
  • AP alternative pathway
  • rRBC rabbit red blood cell
  • NHS normal human serum
  • This erythrocyte lysis assay is based on the formation of terminal complement complex on the surface of the rRBC (rabbit Red Blood Cell) in Normal Human Serum. As a result, the rRBCs are lysed. The progressive decrease in light scatter at 700 nm is a direct measure of erythrocyte lysis.
  • rRBC(s) are incubated in normal human serum in gelatin veronal buffer containing lOmM MgC12/EGTA. Under these conditions, the surface of rRBC triggers the activation of alternative pathway in normal human serum. The alternative pathway activation leads to the formation of C5b-9 complex on the surface of the rRBC(s).
  • AAC3b antibody was incubated with normal human serum (90% NHS) in AP buffer at 37°C with a fixed concentration of rabbit erythrocytes in a temperature controlled ELISA plate reader capable of reading at 700 nm. A progressive decrease in light scatter (due to lysis of intact cells) was measured at 700 nm as a function of time. The data were recorded and analyzed with a SpectraMax 190 plate reader and SoftMax software. For calculation total inhibition was calculated to be at 50 nM in 90% NHS. As shown in FIG. 2, AAC3b inhibits AP mediated hemolysis at 50 nM in 90% normal human serum. The antibody binds C3b and not C3.
  • Example 3 AAC3b antibody inhibits alternative pathway (AP) dependent lysis of rabbit red blood cell (rRBC).
  • AP alternative pathway dependent lysis of antibody sensitized sheep erythrocytes in normal human serum is not inhibited
  • the AP hemolysis assay was conducted as described for Example 2.
  • For the CP lysis assay which was conducted in 2% and 20% normal human serum. Antibody sensitized sheep erythrocytes were incubated with 2% or 20% NHS and data was recorded at OD700 nm as a function of time. The data were recorded and analyzed with a SpectraMax 190 plate reader and SoftMax software.
  • AAC3b did not inhibit classical pathway activation in CP buffer. Thus, AAC3b is a selective inhibitor AP activation but not CP as shown in Fig. 3.
  • Example 4 AAC3b does not bind CIQ in Normal Human Serum
  • CIQ (present in Normal Human Serum) does not bind the substrate -bound AAC3b antibody as shown in Fig. 4.
  • ELISA wells were coated with AAC3b and Avastin and incubated overnight at 4°C. Following incubation, the coating solutions were aspirated and the wells were blocked with 1% BSA in PBS. CIQ is present in serum and therefore was used as a source for CIQ for the assay.
  • Normal human serum at 1% concentration was added to both Avastin and AAC3b coated wells. Following incubation at 37°C for two hours, the plate was washed and the bound CIQ was detected with a 1:2000 dilution of Goat Anti-Clq primary antibody.
  • a Rabbit Anti-Goat HRP was used as the secondary antibody for detection. Following one hour incubation at room temperature, HRP color was developed with TMB solution, which was allowed to incubate for 30min at room temperature. TMB Stop solution was then added to all wells. The plates were read immediately after addition of stop solution in a microplate reader at 450nm. As shown in Fig. 4, AAC3b does not bind C1Q, unlike Avastin, which displayed maximum binding saturation.
  • LPS (4 ⁇ g/100 L) was added to ELISA. Coated wells were blocked with 1% BSA in PBS. A solution of 10% normal human serum in AP buffer (GVB, 10 mM Mg EGTA, pH 7.3) was used as a negative control for total AP activation. To test the effect of AAC3b antibody, various concentrations of this antibody were mixed with 10% NHS. NHS with and without AAC3b was incubated on LPS coated plates at 37°C for 2 hours at RT to allow AP activation to occur.
  • GVB normal human serum in AP buffer
  • Deposited complement components were detected with appropriate antibodies; anti-properdin antibody detected the deposited properdin, anti-C3c antibody detected the deposited C3b and anti-Factor B detected the deposited Bb, and anti- C5b-9 detected the MAC/TCC. Following incubation with the peroxidase conjugated secondary antibody, plates were developed with TMB solution and the color development proceeded for 30min at room temperature. TMB Stop solution was then added to all wells and the plates were read at 450 nm.
  • Figs. 5, 6, 7, 8, 9 demonstrate dose-dependent inhibition of properdin formation and deposition, C3b formation and deposition, Bb formation and deposition, and C5b-9 formation and deposition. These data demonstrate that AAC3b antibody inhibits the formation of both AP C3 and AP C5 convertases in 10 % NHS. Fig. 10 shows data on MAC inhibition. These results demonstrate that the AAC3b antibody is capable to preventing the formation and deposition of C3/C5 convertases and MAC formation and deposition.
  • Antibodies with similar CDRs sequences are expected to bind to the same epitope on a target antigen. Minor changes in the amino acid sequences of the CDRs may reduce the binding affinity of the antibody to the target antigen but still compete with the antibody for binding. Depending upon the situation, one may see 100% competition or as low as 50% competition. Antibodies that compete with the AAC3b antibody exhibit similar pharmacological effects in vivo.
  • ELISA wells were coated with 1 ⁇ g/100 per well of the C3b. Plates were incubated with the coating solution in cold at 4°C over night. The coating solutions were aspirated and wells were treated with 1% BSA in PBS for 2 hours at room temperature. Biotinylated AAC3b antibody at fixed concentration was mixed with various concentrations of unlabeled AAC3b and this solution was aliquoted into the C3b coated wells. Following a 2 hour incubation at RT, the plate was rinsed with PBS and incubated with 1:2000 diluted peroxidase-conjugated neutravidin. Following this incubation, the plate was rinsed and the bound peroxidase was identified using TMB reagent.
  • TMB solution KPL, Gaithersburg, MD
  • TMB Stop solution KPL, Gaithersburg, MD
  • the plate(s) were read in a microplate reader at 450nm.
  • unlabeled AAC3b antibody competes with Biotinylated AAC3b antibody suggesting that both antibodies share the same epitope on C3b.
  • Example 7 Aglvcosylated Fc does not bind to CD16a, CD16b or CD32a/b/c
  • BIACORE methods were used for evaluating this binding. Appropriate Fc receptors were coated and the binding was evaluated. As shown in Figs. 11 and 12, aglvcosylated Fc has low to no binding to Fc receptors except FcRn.
  • Example 8 Heavy chain profile from multiple aglycosylated AAC3b is shown.
  • An antibody can be constructed from any Heavy chain variable region linked to any heavy chain constant region as shown in Figs. 13, 15, 16, 17, 18, 19, 20 and 21.
  • a murine monoclonal antibody harboring the CDRs was sequenced and the CDRs were grafted in human framework regions. Following codon optimization, the sequences were expressed in CHO cells for the production of AAC3b antibodies.
  • Aglycosylated antibodies and its fragments can be expressed in any type of CHO cells or any cell that can express mammalian antibodies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un anticorps anti-C3b humanisé aglycosylé (AAC3b) ou un fragment de liaison d'antigène de celui-ci comprend une modification au niveau d'un site à liaison N conservé dans les domaines CH2 d'une partie Fc de l'anticorps ou du fragment de liaison d'antigène de celui-ci.
PCT/US2017/015856 2016-02-01 2017-01-31 Anticorps anti-c3b aglycosylés et leurs utilisations WO2017136350A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/012,457 US20190202898A9 (en) 2012-04-03 2016-02-01 AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US15/012,457 2016-02-01

Publications (1)

Publication Number Publication Date
WO2017136350A1 true WO2017136350A1 (fr) 2017-08-10

Family

ID=59500847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/015856 WO2017136350A1 (fr) 2016-02-01 2017-01-31 Anticorps anti-c3b aglycosylés et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2017136350A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112949A1 (en) * 2004-06-22 2008-05-15 Tolerx. Inc. Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
WO2013152024A1 (fr) * 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc Anticorps anti-facteur c3 humanisés et chimériques, et leurs utilisations
US20150315268A1 (en) * 2012-10-04 2015-11-05 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
US20160333079A1 (en) * 2012-04-03 2016-11-17 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112949A1 (en) * 2004-06-22 2008-05-15 Tolerx. Inc. Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
WO2013152024A1 (fr) * 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc Anticorps anti-facteur c3 humanisés et chimériques, et leurs utilisations
US20160333079A1 (en) * 2012-04-03 2016-11-17 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20150315268A1 (en) * 2012-10-04 2015-11-05 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BORROK, MJ ET AL.: "Revisiting the Role of Glycosylation in the Structure of Human IgG Fc", ACS CHEMICAL BIOLOGY, vol. 7, no. 9, 10 July 2012 (2012-07-10), pages 1 - 16, XP055363306 *
HAYES, JM ET AL.: "Glycosylation and Fc receptors", INFC RECEPTORS, vol. 382, 2014, pages 165 - 199, XP055189401 *
JUNG, ST ET AL.: "Engineering an Aglycosylated Fc Variant for Enhanced FcyRI Engagement and pH-dependent Human FcRn Binding", BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, vol. 19, no. 5, 1 September 2014 (2014-09-01), pages 780 - 789, XP055318860 *
SAZINSKY, SL ET AL.: "Aglycosylated Immunoglobulin G1 Variants Productively Engage Activating Fc Receptors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 51, 12 December 2008 (2008-12-12), pages 20167 - 20172, XP009143223 *
VIRA, S ET AL.: "Fluorescent Labeled Antibodies - Balancing Functionality and Degree of Labeling", ANALYTICAL BIOCHEMISTRY, vol. 402, no. 2, 31 March 2010 (2010-03-31), pages 1 - 11, XP027060715 *

Similar Documents

Publication Publication Date Title
JP6244350B2 (ja) ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
EP2841453B1 (fr) Anticorps anti-facteur c3 humanisés et chimériques, et leurs utilisations
US8193329B2 (en) Nucleic acids encoding anti-factor D antibodies
US20100111946A1 (en) Inhibiting activation with human anti-factor c3 antibodies and use thereof
CN116333147A (zh) 用于治疗各种疾病和病症的抑制masp-3的组合物和方法
CA3006092A1 (fr) Fragments fab anti-complement de facteur c1q et leurs utilisations
JP2009516506A (ja) 抗アルファ２インテグリン抗体およびその使用
US20100015139A1 (en) METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
EP2545075B1 (fr) Anticorps anti-properdine humanisés et chimériques
US20190225678A1 (en) Anti-c5 antibody for treating patients with complement c5 polymorphism
US20160333079A1 (en) AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20160333080A1 (en) AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOF
WO2017136355A1 (fr) Anticorps anti-bb aglycosylés et leurs utilisations
WO2017136350A1 (fr) Anticorps anti-c3b aglycosylés et leurs utilisations
JP2024075584A (ja) アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
CN113754763A (zh) 分离的抗原结合蛋白及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17748019

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17748019

Country of ref document: EP

Kind code of ref document: A1